following a full submission assessed under the end of life and orphan equivalent process:
sotorasib (Lumykras ®) is accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and future reassessment.
Indication under review: as monotherapy for the treatment of adult patients with KRAS G12C-mutated, locally advanced or metastatic, non-small cell lung cancer (NSCLC), who have progressed on, or are intolerant to platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotherapy.
In a single-arm, phase II study, 37% of previously treated patients with advanced or metastatic, KRAS G12C-mutated NSCLC who received sotorasib achieved an objective response.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
This advice applies only in the context of an approved NHSScotland Patient Access
Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
- Medicine name:
- sotorasib (Lumykras)
- SMC ID:
As monotherapy for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have progressed on, or are intolerant to, platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotheray
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Interim acceptance
- Date advice published
- 07 March 2022